Physician profile
Edward H Jaccoma
NPI 1982681367
$8,659.02
in general payments reported to CMS, 2019-2025
22 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $452 · 2021: $807 · 2022: $1,493 · 2023: $1,785 · 2024: $1,965 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,520.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,514.03 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,008.72 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $934.18 | 2022-2025 | Miebo, Xiidra, Infuse |
| Allergan, INC. | $674.39 | 2019-2022 | |
| Oyster Point Pharma, INC. | $658.67 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $592.12 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $545.37 | 2020-2023 | |
| Biotissue Holdings INC. | $539.08 | 2020-2025 | |
| Alcon Vision LLC | $419.43 | 2022-2025 | Rocklatan, Rhopressa, Eysuvis |
| Mallinckrodt Hospital Products INC. | $338.63 | 2021-2025 | Acthar |
| Dompe US, INC. | $261.00 | 2021-2025 | Oxervate |
| Horizon Therapeutics Plc | $243.95 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $242.75 | 2019-2021 | |
| Amgen INC. | $169.66 | 2024-2025 | Tepezza, Uplizna |
| Thea Pharma INC. | $135.32 | 2023-2025 | Iyuzeh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $125.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $116.55 | 2019-2021 | |
| Sight Sciences, INC. | $53.45 | 2021 | |
| Astellas Pharma US INC | $27.41 | 2024 | Izervay |
| Glaukos Corporation | $25.22 | 2024 | Idose |
| Lkc Technologies, INC. | $17.35 | 2025 | |
| Ocular Therapeutix, INC. | $16.74 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Jaccoma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.